Hims & Hers Shares Jump as Trump’s FDA Pick Seen as Major Ally

Bloomberg01:32

(Bloomberg) -- Hims & Hers Health Inc. shares surged as much as 18% and are on track to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486531440?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jm7H6QP.VRy0p5yVU9EeLg--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_842/7bbd5c600bd0541be916d3977721fd7d","is_english":true,"pubTime":"2024-11-26 01:32","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486531440","market":"us","top_or_hot":-1,"title":"Hims & Hers Shares Jump as Trump’s FDA Pick Seen as Major Ally","media":"Bloomberg","content":"<div>\n<p>(Bloomberg) -- Hims & Hers Health Inc. shares surged as much as 18% and are on track to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-...</p>\n\n<a href=\"https://finance.yahoo.com/news/hims-hers-shares-jump-trump-173234257.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Shares Jump as Trump’s FDA Pick Seen as Major Ally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Shares Jump as Trump’s FDA Pick Seen as Major Ally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-26 01:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hims-hers-shares-jump-trump-173234257.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Hims & Hers Health Inc. shares surged as much as 18% and are on track to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-...</p>\n\n<a href=\"https://finance.yahoo.com/news/hims-hers-shares-jump-trump-173234257.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://finance.yahoo.com/news/hims-hers-shares-jump-trump-173234257.html","article_id":"2486531440","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jm7H6QP.VRy0p5yVU9EeLg--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_842/7bbd5c600bd0541be916d3977721fd7d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486531440","pubTimestamp":1732555954,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":" -- Hims & Hers Health Inc. shares surged as much as 18% and are on track to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-elect Donald Trump’s nomination of Marty Makary to lead the Food and Drug Administration.Hunterbrook said in a Monday report that Hims & Hers may have “a key ally” in Makary, who is an executive at Sesame Inc., a startup that also sells compounded GLP-1 weight loss drugs. Hunterbrook’s hedge fund, Hunterbrook Capital, said it’s long Hims shares, reversing a June short bet, which had focused on online sales of the firm’s compounded GLP-1 injections.Hims & Hers didn’t immediately respond to a request for comment.Hims & Hers shares have gyrated this year after the company started offering copycat versions of GLP-1 injections that are not approved by the FDA. The company is allowed to sell those drugs due to shortages for FDA-approved brand name medications sold by Eli Lilly & Co. and Novo Nordisk A/S.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LLY":"礼来","BK4561":"索罗斯持仓","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2063271972.USD":"富兰克林创新领域基金","BK4534":"瑞士信贷持仓","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4007":"制药","SG9999015978.USD":"利安颠覆性创新基金A","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","ALLY":"Ally Financial Inc.","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4581":"高盛持仓","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD"},"translate_title":"特朗普选择FDA作为主要盟友，Hims&Hers股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLY":1,"LLY":0.9},"content_text":"(Bloomberg) -- Hims & Hers Health Inc. shares surged as much as 18% and are on track to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-elect Donald Trump’s nomination of Marty Makary to lead the Food and Drug Administration.\nHunterbrook said in a Monday report that Hims & Hers may have “a key ally” in Makary, who is an executive at Sesame Inc., a startup that also sells compounded GLP-1 weight loss drugs. Hunterbrook’s hedge fund, Hunterbrook Capital, said it’s long Hims shares, reversing a June short bet, which had focused on online sales of the firm’s compounded GLP-1 injections.\nHims & Hers didn’t immediately respond to a request for comment.\nHims & Hers shares have gyrated this year after the company started offering copycat versions of GLP-1 injections that are not approved by the FDA. The company is allowed to sell those drugs due to shortages for FDA-approved brand name medications sold by Eli Lilly & Co. and Novo Nordisk A/S.\nShares of the telehealth company jumped Nov. 21 when a court document showed the FDA needs more time to determine if Eli Lilly’s GLP-1, tirzepatide, should remain off the shortage list. The FDA took it off the list in October, but then was sued by a compounding trade association and is reconsidering its decision. Hims & Hers doesn’t sell compounded tirzepatide. Novo’s drug, semaglutide, is still listed as “currently in shortage” by the FDA. \nShares of Hims & Hers have rallied more than 200% so far this year, on track for their best annual performance since the company listed on the public markets. \nStill, Wall Street remains cautious about the company, with more than half of analysts covering the stock giving it a hold or sell rating, according to data compiled by Bloomberg. Nearly 40% of analysts covering Hims & Hers recommend buying shares.\n©2024 Bloomberg L.P.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"Policy And Regulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486531440"}